Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence. Read More ›

Sacituzumab govitecan-hziy, for the second-line treatment of patients with metastatic triple-negative breast cancer, is a cytotoxic drug that has specific storage, reconstitution, and administration instructions for adherence. Read More ›

The optimal risk-to-benefit dosage of sacituzumab govitecan-hziy is 10 mg/kg, calculated from dose-escalation and dose-expansion studies. Read More ›

Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes. Read More ›

The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer and BRCA1 or BRCA2 mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

In patients receiving treatment with CDK4/6 inhibitors, levels of neutralizing antibodies post-vaccination were similar to those in matched healthy controls. Read More ›

Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events. Read More ›

To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications. Read More ›

Study shows no compromise in treatment safety or efficacy associated with dose reduction of ribociclib. Read More ›

Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations. Read More ›